Skip to content
Monoceros Biosystems Logo Monoceros Biosystems Logo Monoceros Biosystems Logo
  • Home
  • The Team
  • Careers
  • News
  • Contact us

Cancer-Discovery2

  1. Home
  2. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
  3. Cancer-Discovery2
Previous

Cancer-Discovery2

By Michael Jaramillo|2023-09-11T20:41:39-07:00September 11th, 2023|0 Comments

Share This Story, Choose Your Platform!

FacebookXRedditLinkedInTumblrPinterestVkEmail

About the Author: Michael Jaramillo

Leave A Comment Cancel reply

Copyright 2017 - 2023 Monoceros Biosystems, LLC | All Rights Reserved | Patient Data Privacy Policy
Page load link
Go to Top